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Abstract Insulin-induced net hepatic glucose uptake depends on
the sensing by muscarinic, intrahepatic nerves of a glucose
concentration gradient between portal vein and hepatic artery.
The function of these intrahepatic nerves was examined in
streptozotocin-diabetic rats. In the presence of the glucose
gradient insulin induced net glucose uptake in isolated perfused
livers from control and acutely diabetic but not from chronically
diabetic animals. The neurotransmitter acetylcholine still mim-
icked the existence of the gradient, excluding a metabolic
impairment of livers of chronically diabetic animals. The
impairment of the intrahepatic nerves due to diabetic neuropathy
could contribute to postprandial hyperglycemia in diabetes
mellitus.
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1. Introduction
Net glucose uptake in the liver and subsequent incorpora-
tion into glycogen is under the control of insulin [1]. However,
only when glucose was o¡ered via the oral route a substantial
net hepatic glucose uptake could be achieved with an infusion
of insulin in man [2] as well as in dogs [3,4]. Insulin failed to
induce a marked net hepatic glucose uptake when glucose was
delivered via a peripheral vein [3,5]. This lack of an e¡ect of
insulin on liver metabolism following peripheral glucose infu-
sion was found to be due to the absence of a portals arterial
glucose concentration gradient, which is established following
absorption of a normal oral glucose load. The importance of
this gradient was demonstrated with conscious, chronically
catheterized dogs [3] and with isolated, bivascularly perfused
rat livers [6]. Only in the presence of a glucose concentration
gradient with the higher concentration in the portal vein was
insulin able to induce net hepatic glucose uptake. The gradient
is sensed and transmitted to the hepatocytes by intrahepatic,
muscarinic nerves [7].
Neuropathy, like microangiopathy and retinopathy, is one
of the most common late complications of diabetes mellitus
[8,9]. The reported prevalence varies considerably, depending
on the criteria used for de¢ning diabetic neuropathy. A large
hospital-based study found a prevalence of diabetic peripheral
neuropathy of 22.7% in patients with insulin-dependent dia-
betes mellitus (IDDM) and 32.1% in patients with non-insu-
lin-dependent diabetes mellitus (NIDDM) [10]. The main site
of manifestation of diabetic neuropathy is the sensory system,
leading to hypoesthesia, hyperesthesia and dysesthesia. Dia-
betic neuropathy can also a¡ect the autonomous nervous sys-
tem and, only rarely, the motor nerves. In a multicenter study
using two measures of abnormality 22.1% of patients with
NIDDM and 16.8% of those with IDDM showed cardiac
autonomic dysfunction [11]. In addition, a severe impairment
of the sympathetic hepatic nerves could be demonstrated in
isolated perfused livers of 3 months streptozotocin-diabetic
rats [12].
Therefore, it was the aim of the present investigation to
evaluate the possible functional impairment due to a chroni-
cally diabetic state of the intrahepatic nerves, which sense the
glucose concentration gradient between portal vein and hep-
atic artery and transmit a corresponding signal to the hepa-
tocytes.
2. Materials and methods
2.1. Materials
All chemicals were of reagent grade and from commercial sources.
Enzymes were provided by Boehringer (Mannheim, Germany), insu-
lin, atropine, acetylcholine and streptozotocin were obtained from
Sigma (Deisenhofen, Germany) and bovine serum albumin from Ap-
pli Chem (Darmstadt, Germany).
2.2. Animals
Male Wistar rats were obtained from Harlan-Winkelmann (Borch-
en, Germany). The rats were subjected to a 12-h day-night rhythm (7
a.m.^7 p.m.) for at least one week. All rats had free access to food
and water (standard diet of Ssni¡, Soest, Germany). The perfusion
experiments were started between 9 and 10 a.m.
2.3. Induction of diabetes
To induce diabetes mellitus rats (120^140 g in the chronic diabetes
group and 250^290 g in the acute diabetes group) were starved for 24
h and streptozotocin (50 mg/kg, 33 g/l dissolved in 50 mmol/l sodium
citrate, pH 4.5) was injected intraperitoneally. Thereafter the animals
had free access to food and were used in the experiments after
3 months or 48 h of streptozotocin injection.
Treatment of the animals was in accordance with the German Law
on the Protection of Animals and was performed with permission of
the State Animal Welfare Committee.
2.4. Bivascular liver perfusion
The preparation of the isolated, bivascularly perfused rat liver has
been described in detail earlier [13,14]. In brief, it is an in situ perfu-
sion without recirculation via both the portal vein and the hepatic
artery. Following anesthesia by an intraperitoneal injection of pento-
barbital (40 mg/kg) and a midline laparotomy the rat was killed by an
i.v. overdose of pentobarbital. Blood and urine samples were drawn
by puncturing of femoral artery and urinary bladder for subsequent
determination of the glucose concentrations. Then a catheter was in-
troduced into the portal vein (PV), and the inferior vena cava (IVC)
was incised longitudinally; then the liver perfusion was started via the
PV. Following splenectomy and gastrectomy the intestine was re-
moved by ligating the radix mesenterii and the common hepatic artery
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(HA) was directly cannulated. At this stage the additional perfusion
via the artery was started and a bivascular liver perfusion was estab-
lished with a low pressure component via the PV (10 mmHg (1.33
kPa), 80^60% of total £ow) and a high pressure component via the
HA (60^70 mmHg (7.89^9.31 kPa), 20^40% of total £ow) resulting in
a total £ow of 4 ml/min/g organ weight. An out£ow catheter was
placed in the IVC at the in£ow of the hepatic veins. Finally the thorax
was opened and IVC and aorta were ligated. Experiments were started
following a preperfusion period of 20 min.
The perfusion medium was an erythrocyte-free Krebs-Henseleit-bi-
carbonate bu¡er containing 5 mmol/l glucose, 2 mmol/l lactate, 0.2
mmol/l pyruvate and 0.5% bovine serum albumin. As indicated, in
some experiments the glucose concentration was changed to 10 mmol/
l. The medium was equilibrated with O2/CO2 (19:1).
2.5. Infusion of insulin, atropine or acetylcholine
Insulin, atropine or acetylcholine were diluted in the perfusion bu¡-
er containing 0.5% bovine serum albumin to the indicated sinusoidal
concentrations and infused into the PV.
2.6. Determination of metabolites
Perfusion bu¡er samples were taken consecutively in 1-min intervals
and directly chilled on ice. Glucose was determined with glucose de-
hydrogenase (Merck glucose system) [15]. Blood and urine glucose
concentrations were determined with a Beckman glucose analyzer 2
with the glucose oxidase method [16]. Urine samples were centrifuged
and adequately diluted with Beckman dilution solution before glucose
determination.
2.7. Measurement of perfusion £ow rates
Total perfusion £ow was quanti¢ed by fractionating the e¥uate
into calibrated tubes. Portal £ow was measured using a Research
Flowmeter T 106 (Transonic Systems, Ithaca, NY, USA) with the
£ow probe placed in the portal in£ow. The arterial £ow was the
calculated di¡erence between total and portal £ow.
2.8. Statistical analysis
All results were presented as means þ S.E.M. for the indicated num-
ber of experiments.
3. Results
3.1. Characterization of streptozotocin-diabetic rats
The intraperitoneal injection of streptozotocin resulted in
the development of a diabetic state in all treated rats. The
animals showed clinical signs of hyperglycemia (e.g. polydip-
sia and polyuria) within the following 30^50 h. At the time of
the experiments the two streptozotocin-treated groups, the 3-
months chronically diabetic rats and the 48-h acutely diabetic
rats, had increased blood and urine glucose concentrations
(Table 1). In the 3-months diabetic group only rats with blood
glucose concentrations of more than 20 mmol/l were used for
the experiments. Most of the rats that had been diabetic for
3 months in addition showed signs of severe complications of
chronic diabetes, e.g. enlarged bowels and urinary bladders as
well as cataracts. No animal died due to the induction of
diabetes by streptozotocin or during the diabetic period of
3 months.
3.2. Impaired function of intrahepatic nerves in chronically
streptozotocin-diabetic rats
Isolated livers from control rats were supplied with a glu-
cose concentration gradient by infusing medium containing a
high glucose concentration (10 mmol/l) into the portal vein
(PV) and medium containing a lower glucose concentration (5
mmol/l) into the hepatic artery (HA). During the preperfusion
period without infusion of portal insulin hepatic glucose bal-
ance remained unchanged at a basal glucose output of about
0.5 Wmol/min/g organ weight (Fig. 1A). Infusion of insulin
(100 nmol/l) into the PV from the 31st min onwards induced
a shift from basal net glucose output to a net uptake of about
1.5 Wmol/min/g in livers from control rats. In contrast, in
livers from chronically diabetic rats portal insulin infusion
caused only a shift to a minor net glucose uptake of about
0.2 Wmol/min/g (Fig. 1B). In livers from acutely diabetic ani-
mals portal insulin infusion from the 31st min onwards eli-
cited a shift from glucose output to a marked net glucose
uptake of about 1.3 Wmol/min/g (Fig. 1C). Basal hepatic glu-
FEBS 20882 5-10-98
Table 1
Characterisation of the 3-months streptozotocin-diabetic and 48-h streptozotocin-diabetic rats by body weight, blood glucose level and urine
glucose level
Control Diabetes 3 months Diabetes 48 h
Body weight (g) 286 þ 21 304 þ 35 295 þ 12
Blood glucose (mmol/l) 8.2 þ 1.6 27.4 þ 6.3 22.7 þ 5.2
Urine glucose (mmol/l) n.d. 56.3 þ 8.2 48.3 þ 4.7
Values are means þ S.E.M. of eight (control), ¢ve (chronic diabetes) and three (acute diabetes) experiments.
Fig. 1. Impairment by chronic but not acute streptozotocin-induced
diabetes of the insulin-stimulated net glucose uptake in the presence
of a portals arterial glucose concentration gradient in the perfused
rat liver. Livers were perfused via both the portal vein (PV) and
hepatic artery (HA) without recirculation with a Krebs-Henseleit bi-
carbonate bu¡er containing 10 mmol/l (PV) or 5 mmol/l (HA) glu-
cose as indicated in the lower left inset in each panel, 2 mmol/l lac-
tate, 0.2 mmol/l pyruvate and 0.5% bovine serum albumin. Diabetes
was induced by an intraperitoneal injection of streptozotocin
(50 mg/kg) and the rats were used for the experiments 3 months
(chronic) or 48 h (acute) later. Control rats received no injection.
Insulin (100 nmol/l) was infused via the portal vein when indicated.
Values are means þ S.E.M. of the number of experiments given in
parentheses. po, portal; a, arterial.
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cose release in the two groups of diabetic rats was not di¡er-
ent when compared with control rats.
It was shown previously that the portals arterial glucose
concentration gradient was sensed and transmitted to the hep-
atocytes via intrahepatic, muscarinic nerves and that it could
be mimicked by infusing acetylcholine into the PV [7]. To
distinguish between a loss of function of the intrahepatic
nerves and a possible functional impairment of the hepato-
cytes in the chronically diabetic group, the preserved ability of
acetylcholine to mimic the gradient was examined. Therefore,
as a control, liver perfusions were performed with a portal
insulin infusion in the absence of a portals arterial glucose
concentration gradient (PV 5 mmol/l, HA 5 mmol/l). Under
these conditions in livers from control rats the portal infusion
of insulin did not alter the glucose balance; however, the
additional portal infusion of acetylcholine (1 Wmol/l) resulted
in a shift to a clear net glucose uptake with a maximum of 1.2
Wmol/min/g (Fig. 2A). In livers from chronically diabetic ani-
mals portal infusion of insulin in the absence of a glucose
gradient again did not induce a net glucose uptake but the
additional portal infusion of acetylcholine from the 31st min
onwards still induced a shift to a marked net glucose uptake
of about 1.3 Wmol/min/g (Fig. 2B). Apparently, in the chroni-
cally diabetic state the hepatocytes were fully functional, only
the intrahepatic nerves were impaired.
4. Discussion
In the present study a functional impairment of intrahe-
patic, muscarinic nerves involved in the sensing of a portal
s arterial glucose concentration gradient was found in livers
of rats with chronic streptozotocin-induced diabetes mellitus.
In livers of acutely 48 h diabetic rats the function of the intra-
hepatic nerves remained unaltered excluding a possible neuro-
toxic e¡ect of streptozotocin on the intrahepatic autonomous
nerves.
4.1. Impairment of intrahepatic nerve function in chronically
diabetic rats
In livers of rats with 3 months of streptozotocin-induced
diabetes the insulin-elicited net glucose uptake in the presence
of a portals arterial glucose gradient was clearly reduced
when compared with livers from control rats (Fig. 1B vs.
Fig. 1A). This lack of the normal e¡ect of insulin in livers
of chronically diabetic animals could be due to a functional
impairment of the metabolic capacity of the hepatocytes or of
the intrahepatic nerves which sense the portals arterial glu-
cose gradient and transmit a corresponding signal to the hep-
atocytes. In livers of chronically diabetic animals portal insu-
lin was still able to induce net glucose uptake when the
gradient was mimicked by infusion of acetylcholine into the
portal vein (Fig. 2B); this ¢nding indicates that the metabolic
function of the hepatocytes was not critically altered. In line
with this conclusion are the previous observations that in
streptozotocin-diabetic rats the activity of glucokinase [17]
and glycogen synthase [18] were only reduced but not absent,
which may be due to the decreased but still detectable secre-
tion of insulin [17]. Therefore, the lack of the normal insulin
e¡ect should be ascribed to a functional loss of the intrahe-
patic nerves due to diabetic neuropathy.
Diabetic neuropathy is a well known late complication of
IDDM as well as NIDDM [8^10]; it can a¡ect the sensory
and e¡ectory autonomous nervous system (cf. Section 1). In
general, an autonomous neuropathy was found in 17^22% of
patients with IDDM or NIDDM [19]. Histological studies in
diabetic patients revealed an altered morphology of the vagus
nerve including a reduction of the amount of myelinated ¢bers
[20]. Functional studies with streptozotocin-induced diabetes
in rats demonstrated an impairment of sodium-potassium-
ATPase activity in the vagus nerve [21] and, in addition, of
sympathetic hepatic nerves [22].
4.2. Possible pathophysiological signi¢cance of the impairment
of intrahepatic nerves
In the absorptive state the liver removes a substantial part
of the glucose taken up in excess of actual demands and in-
corporates it into glycogen. The sensing of the portals arte-
rial glucose concentration gradient enables the liver to distin-
guish between endogenous and exogenous glucose [7].
Following absorption of normal dietary carbohydrates the
glucose concentration in the draining vessel of the small in-
testine, the portal vein, is increased and thus a glucose con-
centration gradient is established between the portal vein and
hepatic artery. This gradient then allows insulin to stimulate
net hepatic glucose uptake [7], which contributes substantially
to the disappearance of glucose from the blood and thus to
the avoidance of deleterious high blood glucose concentra-
tions.
In patients with IDDM and NIDDM as a part of late
complications an autonomous diabetic neuropathy might im-
pair the sensing of the portal-arterial glucose concentration
gradient, so that net hepatic glucose uptake would become
insulin-insensitive. Therefore, the amount of glucose removed
from the circulation by the liver after a meal would be de-
creased which would contribute to the hyperglycemia in pa-
tients with IDDM in spite of therapy with insulin and
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Fig. 2. Lack of impairment by chronic streptozotocin-induced diabe-
tes of the insulin plus acetylcholine-stimulated net glucose uptake in
the absence of a portals arterial glucose concentration gradient in
the perfused rat liver. Livers were perfused as described in the
legend to Fig. 1. Insulin (100 nmol/l) plus acetylcholine (1 Wmol/l)
was infused when indicated in the absence of a portals arterial glu-
cose concentration gradient (PV and HA = 5 mmol/l). Values are
means þ S.E.M. of the number of experiments given in parentheses.
po, portal; a, arterial.
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NIDDM in spite of treatment with oral antidiabetic drugs or
insulin. Thus, the impairment of the intrahepatic parasympa-
thetic control could deprive the chronically diabetic patient of
an adequate response to postprandial hyperglycemia.
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